# A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection

> **NCT02673489** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 106 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** DCV
- **DRUG:** SOF
- **DRUG:** RBV

## Key facts

- **NCT ID:** NCT02673489
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-15
- **Primary completion:** 2017-03-02
- **Final completion:** 2017-05-26
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2018-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02673489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02673489, "A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02673489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*